Bergenin attenuates bleomycin‐induced pulmonary fibrosis in mice via inhibiting TGF‐β1 signaling pathway. (10th August 2021) - Li, Xiaohe
Abstract : Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease characterized by epithelial cell damage, fibroblast activation, and collagen deposition. IPF has high mortality and limited therapies, which urgently needs to develop safe and effective therapeutic drugs. Bergenin, a compound derived from a variety of medicinal plants, has demonstrated multiple pharmacological activities including anti‐inflammatory and anti‐tumor, also acts as a traditional Chinese medicine to treat chronic bronchitis, but its effect on the pulmonary fibrosis is unknown. In this study, we demonstrated that bergenin could attenuate bleomycin (BLM)‐induced pulmonary fibrosis in mice. In vitro studies indicated that bergenin inhibited the transforming growth factor‐β1 (TGF‐β1)‐induced fibroblast activation and the extracellular matrix accumulation by inhibiting the TGF‐β1/Smad signaling pathway. Further studies showed that bergenin could induce the autophagy formation of myofibroblasts by suppressing the mammalian target of rapamycin signaling and that bergenin could promote the myofibroblast apoptosis. In vivo experiments revealed that bergenin substantially inhibited the myofibroblast activation and the collagen deposition and promoted the autophagy formation. Overall, our results showed that bergenin attenuated the BLM‐induced pulmonary fibrosis in mice by suppressing the myofibroblast activation and promoting the autophagy and the apoptosis of myofibroblasts.